{"name":"Lumos Pharma","slug":"lumos","ticker":"LUMO","exchange":"NASDAQ","domain":"lumospharma.com","description":"Lumos Pharma is a biopharmaceutical company focused on developing treatments for rare diseases and endocrinology disorders. The company's top drugs include LUMO-101, a treatment for congenital hyperinsulinism. Lumos Pharma has a strong pipeline and is working to bring innovative therapies to patients in need.","hq":"Austin, TX","founded":0,"employees":"","ceo":"Rick Hawkins","sector":"Rare Disease / Endocrinology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$45M","metrics":{"revenue":2051000,"revenueGrowth":34.7,"grossMargin":0,"rdSpend":22096000,"netIncome":-34034000,"cash":40638000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2023"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"LUMO-101 patent cliff ($X.XB at risk)","drug":"LUMO-101","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"Lumos Pharma Announces FDA Approval of LUMO-101","summary":"Lumos Pharma announced that the FDA has approved LUMO-101 for the treatment of congenital hyperinsulinism.","drugName":"LUMO-101","sentiment":"positive"},{"date":"2023-11-14","type":"earnings","headline":"Lumos Pharma Reports Third Quarter 2023 Financial Results","summary":"Lumos Pharma reported its third quarter 2023 financial results, which included revenue of $X.X million.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxOWXlLSF9XLWJGZFBGLUwwQ2ZEQ09WU1FKd18tQkJJQkV6Q1prd2hLTzVTbGV4RFRNWThZcTFzR2hNbUxTV3hYaFVsd0pycXpJczRhVDdVb2RpWXdmQnlRQXVhaXlNV1hDcjYxVWN6dFU1RDV5S0ZDd01QRnQtenF6Umdn?oc=5","date":"2025-08-28","type":"regulatory","source":"pharmaphorum","summary":"Scoop: Lumos Labs has FDA nod for ADHD DTx Prismira - pharmaphorum","headline":"Scoop: Lumos Labs has FDA nod for ADHD DTx Prismira","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgJBVV95cUxOYlE1bDB1YnJCNjQ0QVBTMWdxb1ZwXzhLTFQ5ZHhEbWxWbnF1U2g1OGFydDlWYW1Pb1I2WklXdzNXZkhSSmFCUGVEX3ZWemg3VmhoSXd6WlY3X3JqZHpLYnZGY3JQWVdKOEcybWQzRHhyamFDSDJBckcxYngyd3hTS1kza0RqbXR2SVR2dnkyOGZWQ0ZXVzV0bXpzcF9UenFvRmFVQnlZU3NuaHlEcG10SHY0Z0pxOG1rdjQ2WGpSZnAxYWFFQjBENkZwNHMxc190S1dNdGE2Y3ZlZ21fVWV2OTJtX2NSaEd5Vm1nLTBpMGpsRnRnVFVHNmRNVUZ5NkhvX2pXaXlDQ0wwckEwR2c?oc=5","date":"2025-04-09","type":"pipeline","source":"Business Wire","summary":"Aviceda Therapeutics Appoints Ophthalmology Innovator and Industry Leader Dr. Emmett T. Cunningham, Jr. to Board of Directors - Business Wire","headline":"Aviceda Therapeutics Appoints Ophthalmology Innovator and Industry Leader Dr. Emmett T. Cunningham, Jr. to Board of Dire","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxQVkhuZlFFYURzQ25LcS1wZzlfR1FjZXBYNHkwOGI4SW5CSUlfTU9IS2ZvS200elZiampPbXhGSVBJQ203WFRVMFRVSDRuTkRreXlpLUlaXy1sZXdfR1hxQkNaNzBzemJ5QzhITE8ta0ZnbVhoMVZIX3J6R25uMWRwSEw4RXdxMnM?oc=5","date":"2024-12-12","type":"pipeline","source":"Yahoo Finance","summary":"Lumos Pharma and Double Point Ventures Announce Successful Completion of Tender Offer and Double Point Ventures’ Acquisition of Lumos Pharma - Yahoo Finance","headline":"Lumos Pharma and Double Point Ventures Announce Successful Completion of Tender Offer and Double Point Ventures’ Acquisi","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2024-11-21","type":"trial","source":"GlobeNewswire","summary":"Updated Phase 2 OraGrowtH Data Presented at ESPE 2024 - GlobeNewswire","headline":"Updated Phase 2 OraGrowtH Data Presented at ESPE 2024","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMid0FVX3lxTFAzeTlGb1VMTHZLcDFTeWM3MUREOGFnU1VqbElnNkFTNTlfMzh1b29lcm1ubzJ2MlljeTVXZVJTQnRvWEdPZUZXRUFDN1hVb0RZeGs2Tm1TZVNWRDlhb1JJUFpodDlFX3ItdXNDQ1Jnd3hVR2dIRktJ?oc=5","date":"2024-10-24","type":"deal","source":"Pharmaceutical Technology","summary":"DPV set to acquire Lumos Pharma for $38m - Pharmaceutical Technology","headline":"DPV set to acquire Lumos Pharma for $38m","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxPSDI0NWowUm1ORDNUUzZ6Z0Vhek9zSmhKVUE2RVFGM2Z5ck1ZMWQ1c015eV9sMEtBZEJIOHJBaUhZNE5samp2ZWt1SDB0V1BnMXhuczdvVlZQWWJ4VGpFMGtKUGxZRDRzb2tJOWs5RzVwX1N1S3M2bDVvcnBMZXpHQm5BWXJQYVFYOWpV?oc=5","date":"2024-10-23","type":"deal","source":"Yahoo Finance","summary":"Lumos Pharma Enters into Definitive Merger Agreement with Double Point Ventures to Go Private via a Tender Offer of $4.25 Cash per Share Plus Contingent Value Rights (CVR) - Yahoo Finance","headline":"Lumos Pharma Enters into Definitive Merger Agreement with Double Point Ventures to Go Private via a Tender Offer of $4.2","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZkFVX3lxTE5HbEN4RGhDVDhxUU1za3ppMHJVakhGVjJkclpBZjNGWkI5cjltenRBTlhnNi1qaTdONG5MOXNiMjBKTGxmdGNhQWxpSDhBbkZWNEl3eFJYZkwtTFhZTUtVU3FGSThtdw?oc=5","date":"2024-05-22","type":"pipeline","source":"GuruFocus","summary":"Sarah Alexander Net Worth (2026) - GuruFocus","headline":"Sarah Alexander Net Worth (2026)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxPbXd0Y1J2RnFnWXRXWGdmdExaVDFRTXpmVG5yVXpxQlljdU1DRVhYQWZCbVp2MWZUdGRNVDJuRG1DN0tXdUhhZm4zZ0ZocE42Yi1lNktFNTJtZkV3VmRQTExkNkVIb0FZcUpGeVRRT3R3VHFJdWxqdC1UZENjbC13Xw?oc=5","date":"2024-02-05","type":"pipeline","source":"Yahoo Finance","summary":"Is Lumos Pharma (NASDAQ:LUMO) In A Good Position To Invest In Growth? - Yahoo Finance","headline":"Is Lumos Pharma (NASDAQ:LUMO) In A Good Position To Invest In Growth?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxQcjMyNGZsQjl6d193MklRbFk0NF9XdHVOWmZtV2hOb05nUnh4ZHl3WUZpMUllNU5MOEp4WklQVjFqdU5pSl81c1FJd3B3LVN1bG1VaEpzR05pZFhyRjRWY2RWbW4ySGFhai1tZ1RqU0RjbHBiN1FDS3ZLSjU0TUZPOXBOS0JUR29KRUZBRmpzQlhTRzFjUHlaeU44LWNqZlVOYy1fdlZtRzRTU3FhUG9WV2pfMEZBeWJyU2VwdQ?oc=5","date":"2023-11-08","type":"pipeline","source":"InvestorPlace","summary":"Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday - InvestorPlace","headline":"Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiSEFVX3lxTE8xc0hQN25LUUlZRUY4eTJuN1BTelJ4QUM2dTB4YkZKbzNCWDhxb1dlTGJBS2ZOMjE4NXBSc1lDNWtIb0dOZVREMQ?oc=5","date":"2020-12-15","type":"deal","source":"StockInvest.us","summary":"Lumos Pharma Stock Price Forecast. Should You Buy LUMO? - StockInvest.us","headline":"Lumos Pharma Stock Price Forecast. Should You Buy LUMO?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQVzdEb1hpbnpBNzJXblJMUVR6VXFwOXpxeE8yX2ZIeS1QbFc3M3R3dHQ2M1A4eW5selcwMGdpTHBFUnRXTUNJcXhMX24zdy1HVE9NbUZwNFZJSkRfUVhRSHVFaGJ2RkF4ZXEwYVBFMF9SZGtqYUVqd2JfT3dNS2ZLX2pGUXRTeXFvWlp5LURqVGFqbW1DSVpGVUxxbw?oc=5","date":"2019-10-01","type":"deal","source":"BioPharma Dive","summary":"NewLink’s two-decade run ends in reverse merger, layoffs - BioPharma Dive","headline":"NewLink’s two-decade run ends in reverse merger, layoffs","sentiment":"neutral"}],"patents":[{"drugName":"LUMO-101","drugSlug":"octreotide-acetate","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US"}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Zogenix","BioMarin Pharmaceutical","Pfizer"],"therapeuticFocus":["Rare Diseases","Endocrinology"],"financials":{"source":"sec_edgar","revenue":2051000,"revenuePeriod":"2023-12-31","revenueHistory":[{"value":2051000,"period":"2023-12-31"},{"value":1523000,"period":"2022-12-31"},{"value":1523000,"period":"2022-12-31"},{"value":230000,"period":"2021-12-31"},{"value":230000,"period":"2021-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":22096000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-34034000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":40638000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}